Company intelligence / Profile preview

Saga Health

Lund, Skåne län, Sweden

Ownership: Private
Development stage: Other

Overview

SAGA Diagnostics offers a clinically validated, blood-based platform (Pathlight) for highly sensitive and specific detection of molecular residual disease (MRD) in early-stage breast cancer, achieving 100% sensitivity and specificity with a 13.7-month lead time, now commercially available in the U.S.[2][4].

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic testGenetic assay
Industry: Molecular Diagnostics

Partnerships

Various biopharma companies (undisclosed) for MRD testing and research support[2]

Beyond the preview

Go deeper on Saga Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saga Health.

Explore the full profile